Back to All

Diaceutics presents Poster at ESMO Congress 2019

30 September, 2019

Diaceutics PLC (AIM: DXRX), the data analytics and implementation services company which services the global pharmaceutical industry, announces it will present a poster at the 2019 European Society of Medical Oncology Congress (“ESMO”) in Barcelona today. ESMO will run from 27 September – 1 October 2019.

ESMO is the most influential oncology meeting in Europe, in partnership with the EACR (European Association for Cancer Research). The ESMO Congress is the appointment in Europe for clinicians, researchers, patient advocates, journalists and the pharmaceutical industry from all over the world to get together, learn about the latest advances in oncology and translate science into better cancer patient care. 

The Company will present a poster entitled “Known and unknown gene fusion detection capabilities of solid tumour laboratories conducting next generation sequencing in 6 countries”. The Poster focusses on the current next generation sequencing (“NGS”) capabilities in solid tumour oncology laboratories to detect unknown gene fusions, and concludes that labs in the EU have not kept up with the technical advances in NGS testing due to a lack of sufficient funding, which may lead to missed opportunities for improved treatment for patients.

The poster can be viewed via this link

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny